Skip to main content
SpringerLink
Log in

Added Therapeutic Value of Memantine in the Treatment of Moderate to Severe Alzheimer’s Disease

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

When evaluating the added therapeutic value of a drug, evidence of greater overall benefit or at least an add-on benefit is increasingly being required. Therefore, cost-effectiveness in addition to clinical efficacy is an important consideration. The efficacy of a drug must be examined on the basis of clinical trials by measuring specific parameters that are affected by the drug (for example blood pressure with antihypertensive treatment). Today not only efficacy but also patient-relevant changes (patient benefits) must be demonstrated for a drug, often by measuring quality of life. In order to evaluate the benefit of monotherapy with the N-methyl-D-aspartate antagonist memantine in the management of moderate to severe Alzheimer’s disease, a systematic literature review was conducted. The results showed a benefit for memantine in comparison with placebo in terms of a decrease in nursing care, a delay in care dependency and a delay in admission to nursing homes. In addition, an increase in quality of life has been observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III

Similar content being viewed by others

References

  1. Arzneimittelkommission der deutschen Ärzteschaft: Empfehlungen zur Therapie der Demenz. 3. Auflage 2004

  2. Leber P. Guidelines for the clinical evaluation of antidementia drugs, 1st draft. Rockville (MD): US Food and Drug Administration, 1990

    Google Scholar 

  3. Wimo A, Winblad B, Stöffler A, et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics 2003; 21(5): 327–40

    Article  PubMed  CAS  Google Scholar 

  4. Rychlik R, Wertheimer A, Ruschesbap H, et al. Policy decision making and outcomes research in drug utilization. J Public Health 2005; 13: 257–64

    Article  Google Scholar 

  5. Paul JE, Trueman P: ‘Fourth hurdle reviews’, NICE, and database applications. Pharmacoepidemiol Drug Saf 2001; 10(5): 429–438

    Article  PubMed  CAS  Google Scholar 

  6. Ministerie van Volksgezondheit en Sport (VWS): Medicines’ policy in the Netherlands. International Publication Series Health, Welfare and Sport no 15.2002 [online]. Available from URL: http://www.minvws.nl/ [Accessed 2006 Mar 29]

  7. Zentner A, Velasco-Garrido M, Busse R. Methods for the comparative evaluation of Pharmaceuticals. In: Deutsche Agentur für Health Technology Assessment des Deutschen Instituts für Medizinische Dokumentation und Information (Dahta@Dimdi), 1. Auflage 2005. Available from URL: http://www.dimdi.de [Accessed 2006 Mar 29]

  8. Gray JAM. Evidence-based healthcare. New York: Churchill Livingstone, 1997

    Google Scholar 

  9. Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate to severe Alzheimer’s disease. N Engl J Med 2003; 348(14): 1333–41

    Article  PubMed  CAS  Google Scholar 

  10. Winblad B, Poritis N. Memantine in severe dementia: results of the M-best study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135–46

    Article  PubMed  CAS  Google Scholar 

  11. Marder K. Memantine approved to treat moderate to severe AD. Curr Neurol Neurosci Rep 2003; 4: 349–50

    Article  Google Scholar 

  12. Axura: Backround information on the procedure [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/axura/axura.htm [Accessed 2006 May 18]

  13. Doody R, Wirth Y, Schmitt F, et al. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord 2004; 18: 227–32

    Article  PubMed  CAS  Google Scholar 

  14. Farlow MR. NMDA receptor antagonists: a new therapeutic approach for Alzheimer’s disease. Geriatrics 2004; 59(6): 22–7

    PubMed  Google Scholar 

  15. Standridge JB. Pharmacotherapeutic approaches to the treatment of Alzheimer’s disease. Clin Ther 2004; 26: 615–30

    Article  PubMed  CAS  Google Scholar 

  16. Jarvis B, Figgitt DP. Memantine. Drugs Aging 2003; 20(6): 465–76

    Article  PubMed  CAS  Google Scholar 

  17. Danysz W, Parsons CG, Möbius HJ, et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Res 2000; 2: 85–98

    Article  CAS  Google Scholar 

  18. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613–22

    Article  PubMed  CAS  Google Scholar 

  19. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist — a review of preclinical data. Neuropharmacology 1999; 38(6): 735–67

    Article  PubMed  CAS  Google Scholar 

  20. Reisberg B, Doody R, Stöffler A, et al. Is memantine a breakthrough in the treatment of moderate to severe Alzheimer’s disease? Expert Opin Pharmacother 2003; 4(10): 1857–60

    Article  Google Scholar 

  21. Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005; 20: 459–64

    Article  PubMed  CAS  Google Scholar 

  22. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–14

    Article  PubMed  CAS  Google Scholar 

  23. Ikeda M, Fukuhara R, Shigenobu K, et al. Dementia associated mental and behavioural disturbances in elderly people in the community: findings from the first Nakayama study. J Neurol Psychiatry 2004; 75; 146–8

    CAS  Google Scholar 

  24. EMEA (European Medicines Agency) [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/axura/axura.htm [Accessed 2005 Aug 19]

  25. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112–7

    Article  PubMed  Google Scholar 

  26. Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 2006; 21: 175–81

    Article  PubMed  CAS  Google Scholar 

  27. Alzheimer’s Disease International [online]. Available from URL: http://www.alz.co.uk [Accessed 2006 Apr 5]

  28. Falke E, Nissanov J, Mitchell TW, et al. Subicular dendritic arborization in Alzheimer’s disease correlates with neurofibrillary tangle density. Am J Pathol 2003; 163: 1615–21

    Article  PubMed  Google Scholar 

  29. Caro J, Ward A, Ishak K, et al. To what degree does cognitive impairment in Alzheimer’s disease predict dependence of patients on caregivers? BMC Neurol 2002; 2: 6

    Article  PubMed  Google Scholar 

  30. Ávila R, Bottino CMC, Carvalho IAM, et al. Neuropsychological rehabilitation of memory deficits and activities of daily living in patients with Alzheimer’s disease: a pilot study. Braz J Med Biol Res 2004; 37(11): 1721–9

    Article  PubMed  Google Scholar 

  31. The European Agency for the Evaluation of Medicinal Products. Commitee for Propriety Medicinal Products (CPMP). Note for guidance on medicinal products in the treatment of Alzheimer’s disease. CMP/EWP/553/95; London: CPMP, 1997 Sep

  32. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer’s disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001; 16(7): 653–66

    Article  PubMed  CAS  Google Scholar 

  33. The European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products (CPMP/EWP/ 553/95 corrected). Note for guidance on medicinal products in the treatment of Alzheimer’s disease [online]. London: CPMP, 1997 Sep. Available from URL: http://www.eudra.org/emea.html [Accessed 2006 Mar 29]

  34. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ 2005; 331(7512): 321–7

    Article  PubMed  CAS  Google Scholar 

  35. Reisberg B, Doody R, Stöffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63(1): 49–54

    Article  PubMed  Google Scholar 

  36. Launois R, Guilhaume C, Francois C, et al. Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer’s disease in Norway. 6th International Conference on Alzheimer’s and Parkinson’s Diseases; 2003 May 8–12; Seville, Spain

  37. Faculty of Old Age Psychiatry of the Royal College of Psychiatrists. Response to the NICE appraisal consultation document: donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer’s disease [online]. Available from URL: http://www.rcpsych.ac.uk/members/membership/responseNICE_March05.pdf [Accessed 2005 Aug 19]

  38. Kunz R, Ollenschläger G, Raspe H, et. al. Lehrbuch Evidenzbasierte Medizin in Klinik und Praxis. Deutscher Ärzte-Verlag Köln: 2000

  39. Moher D, Schulz KF, Altman DG, et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191–4

    Article  PubMed  CAS  Google Scholar 

  40. Des Jarlais DC, Lyles C, Crepaz N, et al. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND Statement. Am J Public Health 2004 Mar; 94(3): 361–6

    Article  PubMed  Google Scholar 

  41. Sackett DL, Rosenberg WMC, Gray JAM, et al. Evidece based medicine: what it is and what it isn’t. BMJ 1996; 312: 71–2

    Article  PubMed  CAS  Google Scholar 

  42. Fleischhacker WW, Buchgeher A, Schubert H. Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 87–93

    Article  PubMed  CAS  Google Scholar 

  43. Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine, and memantine for Alzheimer disease. Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development, University of Southampton, UK. Health Technol Assess 2006; 10: 1

    Google Scholar 

  44. Antonanzas F, Badenas J, Francois C, et al. Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer’s disease in Spain. Value Health 2003; 6(6): 765

    Article  Google Scholar 

  45. Sastre A, Sherriff F, McShane R. Memantine for dementia [review]. The Cochrane Library 2005, Issue 2 [online]. Available from URL: http://www.theocochranelibrary.com [Accessed 2006 Mar 29]

  46. Feret B, Dicks R. Focus on… memantine. An oral NMDA antagonist for the treatment of moderate-to-severe Alzheimer’s disease. Formulary 2004; 39: 91–103

    Google Scholar 

  47. Ferris SH. Evaluation of memantine for the treatment of AD. Expert Opinion 2003; 4(12): 2305–13

    Article  CAS  Google Scholar 

  48. Förstl H. Memantine: a viewpoint. Drugs Aging 2003; 20(6): 477–8

    Article  Google Scholar 

  49. Francois C, Sintonen H, Sulkava R, et al. Cost effectiveness of memantine in moderately severe to severe AD: a Markov model in Finland. Clin Drug Invest 2004; 24(7): 373–84

    Article  CAS  Google Scholar 

  50. Gysling E. Memantin. Pharma-Kritik 2003; 13: 49–50

    Google Scholar 

  51. Hellwig B. Memantin zur Behandlung der Alzheimer-Demenz. Deutsche Apothekerzeitung 2002; 142(12): 44–7

    Google Scholar 

  52. Ho Y, Chagan L. Memantine: a new treatment option for patients with moderate to severe Alzheimer’s disease. P&T 2004; 29(3): 162–5

    Google Scholar 

  53. Jain KK. Evaluation of memantine for neuroprotection in dementia. Drug Evaluation 2000; 9(6): 1397–406

    CAS  Google Scholar 

  54. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer’s disease. Drugs Aging 2004; 21(9): 607–20

    Article  PubMed  CAS  Google Scholar 

  55. Koch HJ, Szecsey A, Haen E. NMDA-antagonism (memantine): an alternative pharmacological therpeutic principle. Curr Pharm Des 2004; 10: 253–9

    Article  PubMed  CAS  Google Scholar 

  56. Livingston G, Katona C. The place of memantine in the treatment of Alzheimer’s disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2004; 19: 919–25

    Article  PubMed  Google Scholar 

  57. Möbius HJ. Memantine: update on the current evidence. Int J Geriatr Psychiatry 2003; 18: 47–54

    Article  Google Scholar 

  58. Möbius HJ, Stöffler A, Graham SM. Memantine hydrochloride. Pharmacological and clinical profile. Drugs Today 2004; 40(8): 685–95

    Article  PubMed  Google Scholar 

  59. Molinuevo JL, Garcia-Gi V, Villar A. Memantine: an antigluta-matergic option for dementia. Am J Alzheimer’s Dis Other Demen 2004; 19(1): 10–8

    Article  Google Scholar 

  60. National Horizon Scanning Centre: Memantine for Alzheimer’s disease and vascular dementia. Horizon Scanning Review 2001

  61. Anonymous. Memantine for dementia? Drugs Therap Bull 2003; 41 (10): 73-6

  62. Anonymous. Memantine: poor evaluation and uncertain benefit in Alzheimer’s disease. Rev Prescrire 2003; 12 (68): 203-5

  63. Perras C. Memantine for treatment of moderate to severe Alzheimer’s disease. Issues in emerging health technologies CCOHTA 2004; 64 March

  64. Plosker GL, Lyseng-Williamson KA. Memantine: a pharmacoeconomic review of its use in moderate to severe Alzheimer’s disease. Pharmacoeconomics 2005; 23(2): 193–206

    Article  PubMed  Google Scholar 

  65. Porsteinsson AP, Ismail MS. Memantine — a novel therapeutic option for Alzheimer’s disease. Todays Therap Trends 2004; 22819: 17–28

    Google Scholar 

  66. Rive B, Vercelletto M, Damier FD, et al. Memantine enhances autonomy in moderate to severe AD. Int J Geriatr Psychiatry 2004; 19: 458–64

    Article  PubMed  Google Scholar 

  67. Rossom R, Adityanjee, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am J Geriatr Pharmacother 2004 Dec; 2(4): 303–12

    Article  PubMed  CAS  Google Scholar 

  68. Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer’s disease and other neurodegenerative disorders: memantine, a new hope. Pharmacol Res 2005; 51: 1–17

    Article  PubMed  CAS  Google Scholar 

  69. Wilcock GK. Memantine for the treatment of dementia. Lancet Neurol 2003 Aug; 2: 503–5

    Article  PubMed  CAS  Google Scholar 

  70. Winblad B, Jelic V. Treating the full spectrum of dementia with memantine. Int J Geriatr Psychiatry 2003; 18: 41–6

    Article  Google Scholar 

  71. Arnold K, Lehfeld H, Mösler T, et al. Scale properties of the D-scale in severe dementia [abstract]. Neurobiol Aging 1998; 19Suppl. 4S: 30

    Google Scholar 

Download references

Acknowledgements

This study was funded by Merz Pharmaceuticals GmbH. The authors have no potential conflicts of interest that are directly relevant to the contents of this manuscript.

Author information

Authors and Affiliations

  1. Institute of Empirical Health Economics, Am Ziegelfeld 28, D-51399, Burscheid, Germany

    T. Heinen-Kammerer, H. Rulhoff, S. Nelles & R. Rychlik

Authors
  1. T. Heinen-Kammerer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Rulhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Nelles
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Rychlik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Heinen-Kammerer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heinen-Kammerer, T., Rulhoff, H., Nelles, S. et al. Added Therapeutic Value of Memantine in the Treatment of Moderate to Severe Alzheimer’s Disease. Clin. Drug Investig. 26, 303–314 (2006). https://doi.org/10.2165/00044011-200626060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200626060-00001

Keywords

Search

Navigation